找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biomarkers in Cancer; Victor R. Preedy,Vinood B. Patel Living reference work 20200th edition

[復(fù)制鏈接]
樓主: Annihilate
61#
發(fā)表于 2025-4-1 04:35:42 | 只看該作者
Breast Cancer: Serum TPS as a Biomarker,nformation and establishing patient responses to therapy. A main limitation of TPS is that it is not “organ specific,” which impedes diagnostic utility. Additionally, TPS levels are altered according to inflammation conditions, such as liver cirrhosis, ovulation, and menopausal status. Further clini
62#
發(fā)表于 2025-4-1 08:58:46 | 只看該作者
CA 19-9 as a Serum Biomarker in Cancer, used most commonly as a biomarker in pancreatic cancer as a prognostic and predictive tool and less commonly in other malignancies. This chapter will focus mainly on utility of CA 19-9 in pancreatic cancer and biliary tract cancers.
63#
發(fā)表于 2025-4-1 11:27:55 | 只看該作者
Cancer Cardiotoxicity and Cardiac Biomarkers,ike targeted therapy (i.e., trastuzumab) or angiogenesis inhibitors are all associated with some form of cardiac toxicity: while targeted drugs may induce a reversible damage, angiogenesis inhibitors have a prothrombotic activity, which leads to a high incidence of thromboembolic events..Patients we
64#
發(fā)表于 2025-4-1 17:19:43 | 只看該作者
Carcinoembryonic Antigen-Family Cell Adhesion Molecules (CEACAM) as Colorectal Cancer Biomarkers,tigen (CEA) is the biomarker most frequently used in colorectal cancer. It is effective in the surveillance of colorectal cancer patients and in monitoring the efficacy of therapy, whereas it is less useful in colorectal screening. Recent studies indicate that also CEA-related proteins (CEACAMs) are
65#
發(fā)表于 2025-4-1 19:35:51 | 只看該作者
Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytand Ki-67 (MIB-1) overexpression and UroVysion (multicolor fluorescence in situ hybridization kit for detecting copy number aberrations in chromosomes 3, 7, and 17, and the 9p21 locus), are promising for predicting disease progression and tumor recurrence in NMIBC. Further validation with a prospect
66#
發(fā)表于 2025-4-2 01:56:39 | 只看該作者
Circulating Biomarkers in Hodgkin Lymphoma,Although PET/CT is currently the most important tool used, interpretation is imperfect with low false-negative rates countered by high false positives. Furthermore, PET/CT is unavailable in many rural or underprivileged centers and, even in the most advantaged centers, is impractical for frequent te
67#
發(fā)表于 2025-4-2 03:51:29 | 只看該作者
Circulating Tumor Cells as Biomarkers in Cancer,aggressive adjuvant therapy. Furthermore, various studies have shown that temporal monitoring of CTCs can be used to evaluate patient responses to therapy and to detect genetic and phenotypic changes to tumors in real time, allowing more effective treatment guidance.
68#
發(fā)表于 2025-4-2 07:19:50 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-19 00:11
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
观塘区| 淮安市| 遂溪县| 孝昌县| 栾川县| 黄梅县| 兴安县| 曲靖市| 廊坊市| 建瓯市| 黄大仙区| 理塘县| 桐庐县| 阜新| 万年县| 唐山市| 漠河县| 陕西省| 黄浦区| 永德县| 南开区| 尉氏县| 达日县| 济宁市| 辽宁省| 来宾市| 平远县| 小金县| 武清区| 遂川县| 三门峡市| 阜新| 仁怀市| 湟中县| 昌吉市| 扎鲁特旗| 甘孜县| 郯城县| 遂宁市| 陇川县| 彰化县|